Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series
Abstract
Background: Ocrelizumab, an anti-CD20 monoclonal antibody, is widely used to treat multiple sclerosis (MS), inducing profound B-cell depletion and disease remission. However, it may rarely lead to opportunistic infections. We report two patients with MS on ocrelizumab who developed unique complications of anti-CD20 antibody therapy. One patient developed fulminant endophthalmitis, a novel complication that has not been previously reported.
Case presentation: A 38-year-old female of South Asian descent and a 46-year-old White female, both with MS on ocrelizumab, developed disseminated Ureaplasma urealyticum infection which was initially misdiagnosed as reactive arthritis in both cases. Both patients deteriorated following immunosuppression, with one developing fulminant endophthalmitis. Diagnosis was established via broad-range PCR from synovial and ocular samples. Prolonged antimicrobial and glucocorticoid therapy led to resolution in both cases.
Conclusions: Novel B-cell targeting agents can be effective treatments for MS; however, their use may be associated with potentially life-threatening complications. These two cases highlight the diagnostic and therapeutic challenges associated with opportunistic infections in the context of anti-CD20 monoclonal antibody therapy.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Length of stay and mortality associated with healthcare-associated urinary tract infections: a multi-state model
- Development and Validation of a Calculator for Estimating the Probability of Urinary Tract Infection in Young Febrile Children
- Effect of Missing Data Imputation on Deep Learning Prediction Performance for Vesicoureteral Reflux and Recurrent Urinary Tract Infection Clinical Study
- Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial
- Randomized Clinical Trial Using Sterile Single Use and Reused Polyvinylchloride Catheters for Intermittent Catheterization with a Clean Technique in Spina Bifida Cases: Short-Term Urinary Tract Infection Outcomes
- Urinary tract infection after stroke: A narrative review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.